Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.03, Zacks reports.
Black Diamond Therapeutics Trading Down 9.3 %
Shares of Black Diamond Therapeutics stock traded down $0.18 during trading hours on Monday, reaching $1.71. The stock had a trading volume of 386,999 shares, compared to its average volume of 813,060. The firm has a market capitalization of $96.48 million, a price-to-earnings ratio of -1.30 and a beta of 2.52. Black Diamond Therapeutics has a 1 year low of $1.71 and a 1 year high of $7.66. The firm has a 50 day simple moving average of $2.23 and a two-hundred day simple moving average of $3.16.
Wall Street Analysts Forecast Growth
BDTX has been the topic of a number of research analyst reports. Stifel Nicolaus decreased their price target on Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday. Wedbush reissued an "outperform" rating and issued a $11.00 target price (down from $16.00) on shares of Black Diamond Therapeutics in a research report on Friday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Black Diamond Therapeutics currently has a consensus rating of "Buy" and an average target price of $14.40.
View Our Latest Report on Black Diamond Therapeutics
About Black Diamond Therapeutics
(
Get Free Report)
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Featured Stories
Before you consider Black Diamond Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Black Diamond Therapeutics wasn't on the list.
While Black Diamond Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
